The current status of vena caval replacement.
D000818:Animals; D001158:Arteries / Q000637:transplantation; D001164:Arteriovenous Fistula / Q000601:surgery; D001166:Arteriovenous Shunt, Surgical; D001807:Blood Vessel Prosthesis / Q000009:adverse effects; D001808:Blood Vessels / Q000637:transplantation*; D004285:Dogs; D006801:Humans; D008722:Methods; D011093:Polyethylene Terephthalates / Q000627:therapeutic use; D011138:Polytetrafluoroethylene / Q000627:therapeutic use; D011183:Postoperative Complications; D012598:Sclerosis / Q000150:complications; D012828:Silicones / Q000627:therapeutic use; D013577:Syndrome; D013924:Thrombophlebitis / Q000601:surgery; D013927:Thrombosis / Q000601:surgery; D014182:Transplantation, Autologous; D014183:Transplantation, Heterologous; D014184:Transplantation, Homologous; D014652:Vascular Diseases / Q000601:surgery; D014680:Veins / Q000637:transplantation; D014682:Vena Cava, Inferior / Q000473:pathology / Q000601:surgery*; D014683:Vena Cava, Superior / Q000601:surgery*
D011093:Polyethylene Terephthalates; D012828:Silicones; D011138:Polytetrafluoroethylene